ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Addition of Sotagliflozin for T1DM Alters Renal Hemodynamics
August 08, 2019Sotagliflozin (SOTA), a dual sodium-glucose cotransporter 1 inhibitor (SGLT1i) and SGLT2i, is associated with short- and long-term renal hemodynamic changes in patients with type 1 diabetes... -
EMA agrees to review Sanofi's filing for dual SGLT-1/2 inhibitor sotagliflozin in type 1 diabetes
March 30, 2018Sanofi announced Thursday that the European Medicines Agency (EMA) has accepted to review its marketing application for the experimental oral drug sotagliflozin -
Lexicon Reports Additional Positive Data from Sotagliflozin Pivotal Phase 3 Study
August 16, 2017Lexicon Pharmaceuticals announced additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor. -
Lexicon Reports Additional Positive Data from Pivotal InTandem1 Phase 3 Study for Sotagliflozin
May 12, 2017Lexicon Pharmaceuticals announced additional positive data from the Phase 3 inTandem1 study.
Pharma Sources Insight January 2025
